ROBAXISAL C 1/4 400 MG — DIN 01934783
METHOCARBAMOL : 400 MG ACETYLSALICYLIC ACID : 325 MG CODEINE PHOSPHATE : 16.2 MG · GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ROBAXISAL C 1/4?
ROBAXISAL C 1/4 400 MG contains METHOCARBAMOL : 400 MG ACETYLSALICYLIC ACID : 325 MG CODEINE PHOSPHATE : 16.2 MG. It is listed in the Health Canada Drug Product Database under DIN 01934783, held by GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 16-Dec-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ROBAXISAL C 1/4 used for?
Moderate pain due to or associated with skeletal muscle spasm: acute torticollis, strains, sprains, low back pain, tenosynovitis, fracture, trauma, bursitis, myositis, whiplash.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Codeine, Combinations Excl. Psycholeptics cost around the world?
Codeine, Combinations Excl. Psycholeptics is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Hungary publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 31 | 42 | ZAR███.██ |
| Morocco | PPV (public price) | 6 | 6 | MAD███.██ |
| United Kingdom | hospital | 5 | 5 | GBP███.██ |
| United States | acquisition | 3 | 5 | USD███.██ |
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
65 pack listings across 49 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Codeine, Combinations Excl. Psycholeptics pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Codeine, Combinations Excl. Psycholeptics in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
14 holders have a Canadian DIN containing Codeine, Combinations Excl. Psycholeptics, across 25 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| HALEON CANADA ULC | 1 | 1 | ROBAXACET-8 | Sourceable in Canada |
| TEVA CANADA LIMITED | 5 | 0 | METHOXACET-C 1/8, METHOXISAL-C 1/2, METHOXISAL-C 1/4, METHOXISAL-C 1/8, MUSCLE AND BACK PAIN RELIEF-8 | No marketed DIN |
| ROUGIER PHARMA DIVISION OF RATIOPHARM INC | 3 | 0 | ROUNOX CODEINE 30 TAB, ROUNOX CODEINE 60 TAB, ROUTEC AND CODEINE 30 - TAB | No marketed DIN |
| GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC | 2 | 0 | ROBAXISAL C 1/2, ROBAXISAL C 1/4 | No marketed DIN |
| MCNEIL PHARMACEUTICAL, DIVISION OF ORTHO-MCNEIL INC. | 2 | 0 | TYLENOL W CODEINE NO3 TAB, TYLENOL W CODEINE NO4 TAB | No marketed DIN |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 2 | 0 | SPASMHALT-8, SPASMHALT-ASA-8 | No marketed DIN |
| PHARMEL INC | 2 | 0 | PHL-ACET-CODEINE 30, PHL-ACET-CODEINE 60 | No marketed DIN |
| TECHNILAB PHARMA INC. | 2 | 0 | AXACET-C1/8, AXISAL-C1/8 | No marketed DIN |
| ICN CANADA LTD. | 1 | 0 | PAINEX TAB 0.5GR | No marketed DIN |
| JAMP PHARMA CORPORATION | 1 | 0 | MUSCLE AND BACK PAIN RELIEF CAPLETS | No marketed DIN |
| LABORATOIRE RIVA INC. | 1 | 0 | PRACET 30 | No marketed DIN |
| WYETH CONSUMER HEALTHCARE INC. | 1 | 0 | ROBAXISAL C-1/8 TABLETS | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 400 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section). |
| Storage | Not explicitly detailed in provided text (refers to Storage and Stability section). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Codeine, Combinations Excl. Psycholeptics |
|---|---|
| ATC code | N02AA59 |
| AHFS class | 28:08.08 ; 12:20.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01934783 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1934783 |
| Brand name | ROBAXISAL C 1/4 |
| Generic / active ingredient | METHOCARBAMOL : 400 MG ACETYLSALICYLIC ACID : 325 MG CODEINE PHOSPHATE : 16.2 MG |
| Market authorization holder | GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC |
| Health Canada schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA59 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02AA |
| Current status | CANCELLED POST MARKET |
| Status date | 16-Dec-2025 |
| Original market date | 1992-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: For moderate pain associated with muscle spasm. Not for as-needed (prn) use. Tablets must be swallowed whole; do not crush or chew. Use lowest effective dose for shortest duration.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to ingredients; GI obstruction; asthma; respiratory depression; CYP2D6 ultra-rapid metabolizers; pregnancy/breast-feeding; pediatric tonsillectomy/adenoidectomy; active peptic ulcer.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and life-threatening respiratory depression. Risk of fatal overdose if co-ingested with alcohol or benzodiazepines.
Is Codeine, Combinations Excl. Psycholeptics in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PURDUE PHARMA, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 25 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ROBAXACET-8 | 400 MG | TABLET | HALEON CANADA ULC | MARKETED | 01934767 |
| AXACET-C1/8 | 8 MG | TABLET | TECHNILAB PHARMA INC. | CANCELLED (UNRETURNED ANNUAL) | 02237996 |
| AXISAL-C1/8 | 8 MG | TABLET | TECHNILAB PHARMA INC. | CANCELLED (UNRETURNED ANNUAL) | 02237997 |
| METHOXACET-C 1/8 | 8 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02236872 |
| METHOXISAL-C 1/2 | 32.4 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | 01966375 |
| METHOXISAL-C 1/4 | 16.2 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | 01966367 |
| METHOXISAL-C 1/8 | 8 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | 01941895 |
| MUSCLE & BACK PAIN RELIEF - 8 | 325 MG | TABLET | VITA HEALTH PRODUCTS INC | CANCELLED POST MARKET | 02242180 |
| MUSCLE & BACK PAIN RELIEF-8 | 400 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | 02243047 |
| MUSCLE AND BACK PAIN RELIEF CAPLETS | 8 MG | TABLET | JAMP PHARMA CORPORATION | APPROVED | 02258978 |
2 · Same class — other molecules in ATC N02AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Morphine | BAR-MORPHINE SR · DOLORAL SIROP · KADIAN · M-EDIAT · +86 more | 172 | 56 | Yes |
| Hydromorphone | APO-HYDROMORPHONE · APO-HYDROMORPHONE CR · BAR-HYDROMORPHONE CR · DILAUDID · +40 more | 85 | 34 | Yes |
| Oxycodone | ACT OXYCODONE CR · APO-OXYCODONE CR · OXY.IR · OXYCODONE · +16 more | 68 | 28 | Yes |
| Codein, Combinations With Psycholeptics | APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/2 · APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/4 · FIORINAL-C 1/2 · FIORINAL-C 1/4 · +13 more | 17 | 6 | Yes |
| Oxycodone And Naloxone | TARGIN | 4 | 4 | Yes |
| Codeine, Combinations Excl. Psycholeptics | AXACET-C1/8 · AXISAL-C1/8 · METHOXACET-C 1/8 · METHOXISAL-C 1/2 · +21 more | 25 | 1 | Yes |
| Natural Opium Alkaloids | NUMORPHAN INJECTION 1.5MG/ML · NUMORPHAN SUPPOSITORY 5MG · OPANA ER | 6 | 0 | Not in Canada |
| Opium | OPIUM TEINTURE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02AX | Tapentadol · Tramadol | 41 | 30 |
| N02AJ | Codeine And Acetylsalicylic Acid · Codeine And Paracetamol · Hydrocodone And Ibuprofen · Oxycodone And Acetylsalicylic Acid · Oxycodone And Paracetamol · +1 more | 137 | 21 |
| N02AB | Fentanyl · Pethidine | 105 | 17 |
| N02AE | Buprenorphine | 15 | 4 |
| N02AF | Butorphanol · Nalbufine | 5 | 2 |
| N02AG | Opioids In Comb With Antispasmodics | 3 | 0 |
| N02AD | Pentazocine | 3 | 0 |
| N02AC | Dextropropoxyphene · Dextropropoxyphene, Comb Excl Psycholept | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ROBAXISAL C 1/4 called?
The same molecule, Codeine, Combinations Excl. Psycholeptics, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Brunacod | Latin | South Africa |
| Ibupain Forte | Latin | South Africa |
| Spectrapain | Latin | South Africa |
| Codef Cough | Latin | South Africa |
| Docsed | Latin | South Africa |
| Lenazine Forte | Latin | South Africa |
| Mybucod | Latin | South Africa |
| Suncodin Tablets | Latin | South Africa |
| ACTIFED COMPOUND LINCTUS | Latin | Saudi Arabia |
| Adco-Kiddipayne | Latin | South Africa |
| Adco-Metaxol | Latin | South Africa |
| AstraPain Syrup | Latin | South Africa |
| Ban Pain A/F | Latin | South Africa |
| Codeine | Latin | South Africa |
| CODETUX AD | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.